Shares of Pfizer Inc. PFE advanced 1.26% to $26.43 Friday, on what proved to be an all-around favorable trading session for ...

Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...